ArticleScientific reports2017
Low-dose tamoxifen treatment in juvenile males has long-term adverse effects on the reproductive system: implications for inducible transgenics.
Article in Scientific reports, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 51 citations in OpenAlex.
- Clonal dynamics deviate from neutral drift in zebrafish spermatogenesis.bioRxiv : the preprint server for biology · 2026Article
- Microglia Rank signaling regulates GnRH neuronal function and the hypothalamic-pituitary-gonadal axis.Science (New York, N.Y.) · 2026Article
- Omega-3 fatty acids improves tamoxifen-induced sexual dysfunction in male Wistar rats by modulating NO/cGMP signaling and monoamine neurotransmitters activities.Psychopharmacology · 2026Article
- Cre-LoxP and tamoxifen-induced deletion of ovarian quiescin sulfhydryl oxidase 2 showed disruption of ovulatory activity in mice.Journal of ovarian research · 2024Article
- A novel Nlrp3 knock-in mouse model with hyperactive inflammasome in development of lethal inflammation.Clinical and experimental immunology · 2024Article
- Sex-based impact of pancreatic islet stressors in GluCreERT2/Rosa26-eYFP mice.The Journal of endocrinology · 2023Article
- Tamoxifen exacerbates morbidity and mortality in male mice receiving medetomidine anaesthesia.Animal welfare (South Mimms, England) · 2023Article
- Limitations of Tamoxifen Application for In Vivo Genome Editing Using Cre/ERInternational journal of molecular sciences · 2022Article
- Disruption of Growth Hormone Receptor in Adipocytes Improves Insulin Sensitivity and Lifespan in Mice.Endocrinology · 2022Article
- Cre toxicity in mouse models of cardiovascular physiology and disease.Nature cardiovascular research · 2022Article
- Tetracycline response element driven Cre causes ectopic recombinase activity independent of transactivator element.Molecular metabolism · 2022Article
- Tamoxifen administration induces histopathologic changes within the lungs of Cre-recombinase-negative mice: A case report.Laboratory animals · 2022Article
- Inducible SystemicInternational journal of molecular sciences · 2022Article
- Retinoic Acid Receptor Alpha Is Essential in Postnatal Sertoli Cells but Not in Germ Cells.Cells · 2022Article
- Fate-mapping mice: new tools and technology for immune discovery.Trends in immunology · 2022Review
- Article
- Effects of tamoxifen on tendon homeostasis and healing: Considerations for the use of tamoxifen-inducible mouse models.Journal of orthopaedic research : official publication of the Orthopaedic Research Society · 2021Article
- Sex and Tamoxifen confound murine experimental studies in cardiovascular tissue engineering.Scientific reports · 2021Article
- Genetic and Pharmacological Inhibition of PAPP-A Protects Against Visceral Obesity in Mice.Endocrinology · 2020Article
- It takes a neural village: Circuit-based approaches for estrogenic regulation of episodic memory.Frontiers in neuroendocrinology · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The tamoxifen-inducible Cre system is a popular transgenic method for controlling the induction of recombination by Cre at a specific time and in a specific cell type. However, tamoxifen is not an inert inducer of recombination, but an established endocrine disruptor with mixed agonist/antagonist activity acting via endogenous estrogen receptors. Such potentially confounding effects should be controlled for, but >40% of publications that have used tamoxifen to generate conditional knockouts have not reported even the minimum appropriate controls. To highlight the importance of this issue, the present study investigated the long-term impacts of different doses of a single systemic tamoxifen injection on the testis and the wider endocrine system. We found that a single dose of tamoxifen less than 10% of the mean dose used for recombination induction, caused adverse effects to the testis and to the reproductive endocrine system that persisted long-term. These data raise significant concerns about the widespread use of tamoxifen induction of recombination, and highlight the importance of including appropriate controls in all pathophysiological studies using this means of induction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.